These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 3516430)
21. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Nath CE; Shaw PJ; Montgomery K; Earl JW Br J Clin Pharmacol; 2005 Mar; 59(3):314-24. PubMed ID: 15752378 [TBL] [Abstract][Full Text] [Related]
22. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432 [TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Woodhouse KW; Hamilton P; Lennard A; Rawlins MD Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181 [TBL] [Abstract][Full Text] [Related]
24. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Pritchard J; McElwain TJ; Graham-Pole J Br J Cancer; 1982 Jan; 45(1):86-94. PubMed ID: 7037033 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Bosanquet AG; Gilby ED Cancer Chemother Pharmacol; 1984; 12(3):183-6. PubMed ID: 6705135 [TBL] [Abstract][Full Text] [Related]
26. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270 [TBL] [Abstract][Full Text] [Related]
27. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Tattersall MH; Jarman M; Newlands ES; Holyhead L; Milstead RA; Weinberg A Eur J Cancer (1965); 1978 May; 14(5):507-13. PubMed ID: 648565 [No Abstract] [Full Text] [Related]
28. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of melphalan in isolated perfusion of the limbs. Benckhuijsen C; Varossieau FJ; Hart AA; Wieberdink J; Noordhoek J J Pharmacol Exp Ther; 1986 May; 237(2):583-8. PubMed ID: 3701643 [TBL] [Abstract][Full Text] [Related]
30. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274 [TBL] [Abstract][Full Text] [Related]
31. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005 [TBL] [Abstract][Full Text] [Related]
32. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. Mahoney DH; Strother D; Camitta B; Bowen T; Ghim T; Pick T; Wall D; Yu L; Shuster JJ; Friedman H J Clin Oncol; 1996 Feb; 14(2):382-8. PubMed ID: 8636747 [TBL] [Abstract][Full Text] [Related]